British man tests first personalised melanoma vaccine

 An important trial of the world's first "personalised" mRNA vaccine against the deadliest form of skin cancer - melanoma - is now under way in the UK.

 

Steve Young, 52, from Stevenage, Herts, who had a melanoma growth cut out of his scalp last August, is one of the first patients to try the shot.

It is designed to help his immune system recognise and wipe out any remaining cancerous cells.  

And hopefully, that means his cancer will not return.

The jab, mRNA-4157 (V940), uses the same technology as current Covid vaccines and is being tested in final-stage Phase III trials.

 

Genetic signature

The combined treatment, made by Moderna and Merck Sharp and Dohme (MSD), is not yet available routinely on the NHS, outside of clinical trials.

 

Experts in some other countries, including Australia, are also trying it on patients, to gather more evidence and see whether it should be rolled out more widely.

 

The vaccine is personalised - meaning the make-up of it is changed to suit the individual patient.

 

It is created to match the unique genetic signature of the patient's own tumour and works by instructing the body to make proteins or antibodies that attack markers or antigens found only on those cancer cells.

To learn more about the related topics being discussed at the Vaccine Congress 2024, you can join the conference.

For info: https://vaccines.annualcongress.com/